Goldman Sachs’s Palisade Bio PALI Stock Holding History

Goldman Sachs’s Portfolio PALI Stock Details PALI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Hold	0	–	-$555K	–	7438
2015 Q2	–	Hold	0	–	–	–	5096

Other funds holding PALI

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

BGI

B Group Inc Dallas, Texas $135M AUM 80% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Goldman Sachs's PALI Position: Q1 2026 in Review

Goldman Sachs increased its Palisade Bio (PALI) stake by 864% in Q1 2026, buying an estimated $8.76M and bringing the position to 5,373,951 shares worth $9.4M. The position accounts for ﹤0.01% of the portfolio, ranked #3124.

Goldman Sachs first reported a position in PALI in Q2 2015 and has held it in 3 quarters since. 96 funds tracked by Wall St. Rank hold PALI as of Q1 2026.

Goldman Sachs held 5,373,951 shares of Palisade Bio worth $9.4M as of Q1 2026.
Goldman Sachs bought 4,816,386 Palisade Bio shares in Q1 2026, an estimated $8.76M.
Palisade Bio made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3124 holding.
Goldman Sachs first reported a position in Palisade Bio in Q2 2015 and has held it in 3 quarters since.
96 funds tracked by Wall St. Rank held Palisade Bio as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.